Ligandal is creating delivery systems and AI-driven targeting approaches for cell-specific and precision genetic medicine.
Ligandal's mission is to create precision delivery platform to cure and treat disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented precision at the cellular and sub-cellular level. Our ligand discovery engine allows for rapid design of diagnostically-responsive materials, capable of shuttling a variety of nucleic acid and protein payloads (including CRISPR and mRNA) to specific cell types. We are initially applying this technology to indications in hematology, immuno-oncology, and infectious disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 1, 2019 | Seed | $1.80M | — | — | — | Detail |
Oct 24, 2017 | Seed | — | 1 | — | — | Detail |
Oct 1, 2017 | Seed | $2M | 2 | — | — | Detail |
Aug 9, 2016 | Angel | $330K | 10 | — | — | Detail |
Aug 6, 2015 | Angel | $200K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bioverge | — | Seed |
Social Capital | — | Seed |
Social Impact Capital | — | Seed |
D.A. Wallach | — | Angel |
Eric Anschutz | — | Angel |
Esther Dyson | — | Angel |
Jeff Hammerbacher | — | Angel |
Jeremy Yap | — | Angel |
Justin Rosenstein | — | Angel |
Kauffman Fellows | — | Angel |